阿斯利康 (AZN.US)日前宣布，其重磅免疫疗法Imfinzi (durvalumab)已获得欧盟委员会批准，作为单药，用于治疗接受铂类放化疗 (CRT)后病情未进展的成人局限期小细胞肺癌 (LS-SCLC)患者。根据新闻稿，Imfinzi是首个获欧盟委员会批准用于治疗局限期小细胞肺癌的免疫疗法。

阿斯利康公司于近日宣布，其备受瞩目的免疫疗法Imfinzi（durvalumab）已获得欧盟委员会的批准，成为治疗成人局限期小细胞肺癌（LS-SCLC）的首个单药免疫疗法。这一里程碑式的进展标志着在小细胞肺癌的治疗领域开启了新的篇章。根据官方发布的消息，此项批准适用于在接受铂类治疗及放化疗（CRT）后病情未进展的患者。Imfinzi的获批为希望的曙光，它不仅提供了一种新的治疗选择，也为无数患者的未 ...

在医疗界又一重磅消息传来，阿斯利康（AstraZeneca）近期宣布，其开创性的免疫疗法Imfinzi（durvalumab）获得了欧盟委员会的批准。这一疗法专为成人局限期小细胞肺癌（LS-SCLC）患者设计，特别是那些在接受铂类放化疗后病情未进展的患者，成为该领域的首款获得批准的免疫疗法。

其重磅PD-L1抑制剂Imfinzi（durvalumab）与标准治疗FLOT（fluorouracil、leucovorin、oxaliplatin和docetaxel）联用的围手术期治疗方案，在无事件生存期（EFS ...

格隆汇3月19日｜阿斯利康公司日前宣布，其重磅免疫疗法Imfinzi（durvalumab）已获得欧盟委员会批准，作为单药，用于治疗接受铂类放化疗（CRT）后病情未进展的成人局限期小细胞肺癌（LS-SCLC）患者。根据新闻稿，Imfinzi是首个获欧 ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

Updated results from the NIAGARA trial further support perioperative durvalumab and neoadjuvant chemotherapy as a potential new treatment for patients with muscle-invasive bladder cancer, according to ...

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a 'game-changer' study. Patients with advanced ...

Please note that following on from information provided to NICE by the company in February 2024 the appraisal was suspended from NICE’s work programme. As no further information has been received from ...

Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events included hypertension and anemia. Evidence ...